Please assess the completion status of the following clinical trial:

Trial Title: RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 and \< 80 years~2. Prior platinum treatment is required~3. Prior treatment with a checkpoint inhibitor is required unless contraindicated. Maintenance with a checkpoint inhibitor is NOT required~4. Patient must have received at least 2 prior lines of therapy~5. Biopsy confirmation of small cell lung cancer~6. Capable of providing informed consent and complying with trial procedures~7. Measurable disease by RECIST 1.1. Measurable lesions will be confirmed by imaging (CT scan)~8. PS 0-1~Exclusion Criteria:~1. Symptomatic central nervous system metastases or neurologically unstable patients that are on increasing steroid dose.~2. The presence of another primary malignancy (excluding in situ of the cervix or basal carcinoma of the skin)~3. Treatment of SCLC with any antineoplastic agent with the exception of steroids.~4. Patients with clinically significant illnesses which would compromise participation in the study, including, but not limited to active or uncontrolled infection, immune deficiencies, Hepatitis B, Hepatitis C, uncontrolled diabetes, uncontrolled hypertension, certain heart conditions, or mental illness/social situations that would limit compliance with study requirements.~5. History of an allergic reaction to previously received platinum-based regimen, or history of having to discontinue previously received platinum-based regimen secondary to toxicity (excluding hematologic toxicity)~6. Any clinical laboratory findings, which give reasonable suspicion of a disease or condition that contraindicates the use of any study medication or renders the patient at high risk from treatment~7. Uncontrolled or symptomatic pleural or pericardial effusion~8. Pregnant or nursing. There is a potential for congenital abnormalities and for this regimen to harm nursing infants

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): RRx-001 + eLOOP Device 4 mg IV infusion once weekly for 3 weeks~Cisplatin/carboplatin plus etoposide (up to 4 cycles):~1. Cisplatin or Carboplatin:~   1. Cisplatin initially dosed at 60 mg/m2 on Day 1 every 3 weeks OR~  2. Carboplatin initially dosed at an AUC (area under the curve) of 5 on Day 1 every 3 weeks~2. Etoposide to be given per the initial approval by the package insert (USPI FDA) at 100 mg/m2 Days 1-3 every 3 weeks
- Arm 2 (Type: ACTIVE_COMPARATOR): Cisplatin/carboplatin plus etoposide (up to 4 cycles):~1. Cisplatin or Carboplatin:~   1. Cisplatin initially dosed at 60 mg/m2 on Day 1 every 3 weeks OR~  2. Carboplatin initially dosed at an AUC of 5 on Day 1 every 3 weeks~2. Etoposide to be given per the initial approval by the package insert (USPI FDA) at 100 mg/m2 Days 1-3 every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility